Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
C12Q-001/68
C12N-009/96
C07H-021/04
출원번호
UP-0192655
(2008-08-15)
등록번호
US-7670605
(2010-04-21)
발명자
/ 주소
Hubbell, Jeffrey A.
Elbert, Donald L.
Schoenmakers, Ronald
출원인 / 주소
Eidgenossische Technische Hochschule Zurich
Universitat Zurich
대리인 / 주소
Bieker-Brady, Kristina
인용정보
피인용 횟수 :
4인용 특허 :
32
초록
The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
대표청구항▼
What is claimed is: 1. A biomaterial comprising a pharmaceutically active moiety, a water-soluble or water-swellable polymer, and a linker comprising a thioether or secondary amine, wherein said linker connects said pharmaceutically active moiety and said polymer, and said pharmaceutically active m
What is claimed is: 1. A biomaterial comprising a pharmaceutically active moiety, a water-soluble or water-swellable polymer, and a linker comprising a thioether or secondary amine, wherein said linker connects said pharmaceutically active moiety and said polymer, and said pharmaceutically active moiety is connected to said linker via an ester or amide bond, said bond having a half-life of between 1 hour and 1 year in an aqueous solution at pH 7.4 and 37° C. 2. The biomaterial of claim 1, wherein the half-life of the ester or amide bond is between 1 day and 9 months in an aqueous solution at pH 7.4 and 37° C. 3. The biomaterial of claim 1, wherein the half-life of the ester or amide bond is between 2 days and 6 months, in an aqueous solution at pH 7.4 and 37° C. 4. The biomaterial of claim 1, wherein the half-life of the ester or amide bond is between 4 days and 3 weeks, in an aqueous solution at pH 7.4 and 37° C. 5. The biomaterial of claim 1, wherein said pharmaceutically active moiety is derived from one of the group consisting of synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, biosynthetic proteins or peptides, naturally occurring peptides or proteins, and modified naturally occurring peptides or proteins. 6. The biomaterial of claim 1, wherein said pharmaceutically active moiety is derived from paclitaxel, doxorubicin, 5-fluorodeoxyuridine, estradiol, or 2-methoxyestradiol. 7. The biomaterial of claim 1, wherein said pharmaceutically active moiety connected to said linker has the formula: D-Y—C(O)—(CH2)n—S—(CH2)2—COX—, D-Y—C(O)—(CH2)n—NH—(CH2)2—COX—, D-Y—C(O)—(CH2)n—NH—U—, D-Y—C(O)—(CH2)n—S—U—, D-Y—C(O)—(CH2)2—S-L-S—CH2—CH2—CO—X—, D-Y—C(O)—(CH2)2—S-L-S—U—, D-Y—C(O)—(CH2)2—NH-L-S—CH2—CH2—CO—X—, D-Y—C(O)—(CH2)2—NH-L-S—U—, D-Y—C(O)—(CH2)2—CH2—CH2—CO—X—, D-Y—C(O)—(CH2)2—S-L-NH—U—, D-Y—C(O)—(CH2)2—NH-L-NH—CH2—CH2—CO—X—, or D-Y—C(O)—(CH2)2—NH-L-NH—U—, wherein D said pharmaceutically active moiety; Y is O, NH, or N; L is a linear or branched moiety; X is O or N; n is 1 or 2, and U is the product of the addition of a nucleophile to an electrophilic group that is attached to said water-soluble or water-swellable polymer. 8. The biomaterial of claim 1, wherein said water-soluble or water-swellable polymer is selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(ethylene-co-vinyl alcohol), poly(vinyl pyrrolidone), poly(acrylic acid), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, or water-soluble or water-swellable copolymers comprising these polymers, and their derivatives comprising conjugated unsaturated groups. 9. The biomaterial of claim 1, wherein said linker comprises a hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive. 10. A biomaterial comprising a first component cross-linked to a second component, wherein (i) said first component comprises a first pharmaceutically active moiety, a first water-soluble or water-swellable polymer, and a first linker comprising a thioether or secondary amine, wherein said linker connects said pharmaceutically active moiety and said polymer, and said pharmaceutically active moiety is connected to said linker via a first ester or amide bond, said first bond having a half life of between 1 hour and 1 year in an aqueous solution at pH 7.4 and 37° C.; and (ii) said second component comprises a second pharmaceutically active moiety, a second water-soluble or water-swellable polymer, and a second linker comprising a thioether or secondary amine, wherein said linker connects said pharmaceutically active moiety and said polymer, and said pharmaceutically active moiety is connected to said linker via a second ester or amide bond, said second bond having a half-life of between 1 hour and 1 year in an aqueous solution at pH 7.4 and 37° C., wherein said first and second components are the same or different. 11. The biomaterial of claim 10, wherein said first and second components are cross-linked with a third polymer that comprises two or more conjugated unsaturated groups but does not comprise a pharmaceutically active moiety. 12. The biomaterial of claim 10, wherein said first and second components are cross-linked with a linker comprising two or more nucleophilic groups. 13. The biomaterial of claim 10, wherein said first or second water-soluble or water-swellable polymer is selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(ethylene-co-vinyl alcohol), poly(vinyl pyrrolidone), poly(acrylic acid), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, or water-soluble or water-swellable copolymers comprising these polymers, and their derivatives comprising conjugated unsaturated groups. 14. The biomaterial of claim 10, wherein said first or second polymer, prior to being cross-linked, comprises one or more conjugated unsaturated groups. 15. The biomaterial of claim 14, wherein said conjugated unsaturated groups are selected from the group consisting of acrylates, methacrylates, acrylamides, methacrylamides, acrylonitiriles, and quinones. 16. The biomaterial of claim 10, wherein said first or second linker comprises an adhesion site, growth factor binding site, protease binding site, or enzymatically degradable site. 17. The biomaterial of claim 10, wherein the half life of said first or second ester or amide bond is between 1 day and 9 months in an aqueous solution at pH 7.4 and 37° C. 18. The biomaterial of claim 10, wherein the half life of said first or second ester or amide bond is between 2 days and 6 months, in an aqueous solution at pH 7.4 and 37° C. 19. The biomaterial of claim 10, wherein the half life of the ester or amide bond is between 4 days and 3 weeks, in an aqueous solution at pH 7.4 and 37° C. 20. The biomaterial of claim 10, wherein said pharmaceutically active moiety is derived from one of the group consisting of synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, biosynthetic proteins or peptides, naturally occurring peptides or proteins, and modified naturally occurring peptides or proteins. 21. The biomaterial of claim 10, wherein said pharmaceutically active moiety is derived from paclitaxel, doxorubicin, 5-fluorodeoxyuridine, estradiol, or 2-methoxyestradiol. 22. The biomaterial of claim 10, wherein said first and second components have the formula: D-Y—C(O)—(CH2)n—S—(CH2)2—COX—P, D-Y—C(O)—(CH2)n—NH—(CH2)2—COX—P, D-Y—C(O)—(CH2)n—U—P, D-Y—C(O)—(CH2)n—S—U—P, D-Y—C(O)—(CH2)2—S-L-S—CH2—CH2—CO—X—P, D-Y—C(O)—(CH2)2—S-L-S—U—P, D-Y—C(O)—(CH2)2—NH-L-S—CH2—CH2—CO—x—P, D-Y—C(O)—(CH2)2—NH-L-S—U—P, D-Y—C(O)—(CH2)2—NH-L-NH—CH2—CH2—CO—X—P, or D-Y—C(O)—(CH2)2—NH-L-NH—U—P, wherein D is said first or second pharmaceutically active moiety; Y is O, NH, or N; L is a linear or branched moiety; X is O or N; P is said first or second water-soluble polymer or a water-swellable polymer further comprising one or more conjugated unsaturated groups; n is 1 or 2, and U is the product of the addition of a nucleophile to an electrophilic group that is attached to said first or second polymer. 23. The biomaterial of claim 10, wherein said first or second linker comprises a hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive. 24. The biomaterial of claim 1, wherein said linker comprises said thioether. 25. The biomaterial of claim 1, wherein said linker comprises said secondary amine. 26. The biomaterial of claim 10, wherein said first linker or said second linker comprises said thioether. 27. The biomaterial of claim 10, wherein said first linker or said second linker comprises said secondary amine.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (32)
Greenwald Richard B. (Somerset NJ), Azlactone activated polyalkylene oxides conjugated to biologically active nucleophiles.
Capecchi John T. (Oakdale MN) Heilmann Steven M. (Afton MN) Krepski Larry R. (White Bear Lake MN) Kwon Oh-Seung (Woodbury MN) Olson David B. (May Township ; County of Washington MN), Azlactone-functional substrates, corneal prostheses, and manufacture and use thereof.
Hubbell, Jeffrey A.; Elbert, Donald; Schoenmakers, Ronald, Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill-West Jennifer L. (Austin TX) Hossainy Syed F. A. (Austin TX), Gels for encapsulation of biological materials.
Hubbell Jeffrey A. (Concord MA) Pathak Chandrashekhar P. (Austin TX) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hossainy Syed F. A. (Austin TX), Gels for encapsulation of biological materials.
Hubbell Jeffrey A. ; Pathak Chandrashekhar P. ; Sawhney Amarpreet S. ; Desai Neil P. ; Hill Jennifer L. ; Hossainy Syed F. A., Gels for encapsulation of biological materials.
Hubbell Jeffrey A. ; Pathak Chandrashekhar P. ; Sawhney Amarpreet S. ; Desai Neil P. ; Hossainy Syed F. A., Gels for encapsulation of biological materials.
Rhee Woonza M. ; Berg Richard A. ; Chu George H. ; DeLustro Frank A. ; Jolivette Dan M. ; McCullough Kimberly A., Injectable or implantable biomaterials for filling or blocking lumens and voids of the body.
Harris J. Milton (Huntsville AL), Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for m.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of blood substitutes for in vivo delivery.
Ribi Hans O. (San Mateo CA) Guion Todd A. (Burlingame CA) Murdoch Joseph R. (Burlingame CA) Scott John C. (Los Gatos CA) Pan Victor (Burlingame CA) Choate Glenda L. (Belmont CA), Multi-optical detection system.
Ribi Hans O. (San Mateo CA) Guion Todd A. (Burlingame CA) Murdoch Joseph R. (Burlingame CA) Scott John C. (Los Gatos CA) Pan Victor (Burlingame CA) Choate Glenda L. (Belmont CA), Multi-optical detection system.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill Jennifer L. (Austin TX), Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers.
Vazquez Michael L. ; Mueller Richard A. ; Talley John J. ; Getman Daniel ; DeCrescenzo Gary A. ; Freskos John N., Sulfonylalkanoylamino hydroxyethylamimo sulfonamides useful as retroviral protease inhibitors.
Cha Younsik (Salt Lake City UT) Choi Young Kweon (Salt Lake City UT) Bae You Han (Kwangju KRX), Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers.
Kenan, Daniel James; Hamilton, Paul Theodore, Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.